"Today, Médecins Sans Frontières (MSF, Doctors Without Borders) filed a patent opposition against Pfizer’s vaccine for pneumonia in India. According to an MSF press release, the humanitarian association hopes to prevent United States company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PVC13) so competition can bring cheaper versions to the market... Pneumonia kills almost one million children each year, according to MSF. Pfizer and GlaxoSmithKline (GSK) are the only two companies manufacturing the vaccine. According to the release, “it is now 68 times more expensive to vaccinate a child than in 2001. It refers to a 2015 MSF report, The Right Shot: Bringing down Barriers to Affordable and Adapted Vaccines."
Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD
Showing posts with label vaccine costs. Show all posts
Showing posts with label vaccine costs. Show all posts
Sunday, March 13, 2016
MSF Challenges Pfizer Patent Application For Pneumonia Vaccine In India; Intellectual Property Watch, 3/11/16
Intellectual Property Watch; MSF Challenges Pfizer Patent Application For Pneumonia Vaccine In India:
Subscribe to:
Posts (Atom)